Norddeutscher Rundfunk

Kasten by Veeam’s Kanister Accepted by Cloud Native Computing Foundation (CNCF) as Sandbox Project

Retrieved on: 
Tuesday, November 7, 2023

Kasten by Veeam ®, the market leader for Kubernetes backup and disaster recovery, announced today that Kanister , an open-source framework that provides application-level data backup and recovery, has been accepted by the Cloud Native Computing Foundation (CNCF) as a sandbox project, indicating that the project adds value to the CNCF mission and encourages public visibility within the community.

Key Points: 
  • Kasten by Veeam ®, the market leader for Kubernetes backup and disaster recovery, announced today that Kanister , an open-source framework that provides application-level data backup and recovery, has been accepted by the Cloud Native Computing Foundation (CNCF) as a sandbox project, indicating that the project adds value to the CNCF mission and encourages public visibility within the community.
  • The platform fosters freedom of choice and control of stateful workloads to provide users with a customizable experience that ensures data is well-protected.
  • “Kanister was one of the early projects in the space and has grown up alongside other community projects such as CSI and database operators.
  • To learn more about Kanister’s role in enterprise data protection, visit the Kanister project web site at https://Kanister.io .

35th Maschsee Lake Festival Hannover 2022: A culinary and artistic voyage around the world

Retrieved on: 
Friday, July 15, 2022

The international Big 7 Travel portal has selected the Maschsee Lake Festival Hannover as the only German summer festival in the TOP 10 Food Festivals.

Key Points: 
  • The international Big 7 Travel portal has selected the Maschsee Lake Festival Hannover as the only German summer festival in the TOP 10 Food Festivals.
  • The Maschsee Lake Festival Hannover was awarded the ninth place in the selection procedure published at the start of June.
  • The 35th edition of the Maschsee Lake Festival Hannover will live up to this accolade in full, with this year's range of offerings, and in particular the new culinary concepts.
  • Lindenblatt goes Maschsee Lake Festival Hannover: In collaboration with Aresto, the best from the restaurants "800 Grad" und "Lokal 4" come together at the Maschsee Lake Festival Hannover.

Green Hygienics Holdings Inc. (GRYN) Executes Agreement with Cinvestav, the Leading Mexican Academic Research Institution, to Advance Research Targeting Endocannabinoid System (ECS) Deficiencies

Retrieved on: 
Thursday, May 20, 2021

Cinvestav ranks fourth among research centers in Latin America and ranks 118th in the world.\nDr.

Key Points: 
  • Cinvestav ranks fourth among research centers in Latin America and ranks 118th in the world.\nDr.
  • There\xe2\x80\x99s an urgent need for more effective and safer options.
  • After meeting with leading researchers at Cinvestav\'s Mexico City Campus, we are confident in our collaboration on the development of new and efficacious products," stated Kyle MacKinnon, COO of Green Hygienics.
  • The institute is divided into 10 research centers; 3 of these are in Mexico City, while the others are dispersed across the country.

Green Hygienics Holdings Inc. (GRYN) Executes Agreement with Cinvestav, the Leading Mexican Academic Research Institution, to Advance Research Targeting Endocannabinoid System (ECS) Deficiencies

Retrieved on: 
Thursday, May 20, 2021

Cinvestav ranks fourth among research centers in Latin America and ranks 118th in the world.\nDr.

Key Points: 
  • Cinvestav ranks fourth among research centers in Latin America and ranks 118th in the world.\nDr.
  • There\xe2\x80\x99s an urgent need for more effective and safer options.
  • After meeting with leading researchers at Cinvestav\'s Mexico City Campus, we are confident in our collaboration on the development of new and efficacious products," stated Kyle MacKinnon, COO of Green Hygienics.
  • The institute is divided into 10 research centers; 3 of these are in Mexico City, while the others are dispersed across the country.

Award-winning 'Loneliness Trilogy' Book Series Adaptation In Works From Travis Payne Productions

Retrieved on: 
Thursday, May 13, 2021

Known as the "Oliver Sacks of law," Dr. Terry\'s first television project leverages his groundbreaking research on the topic of loneliness.\nDr.

Key Points: 
  • Known as the "Oliver Sacks of law," Dr. Terry\'s first television project leverages his groundbreaking research on the topic of loneliness.\nDr.
  • Each of the prize-winning books has garnered 97% five (5) star reviews on Amazon, as well as high praise from multiple Harvard Medical School psychiatry professors.
  • "\nTPP\'s Travis Payne is largely known for his contributions to large-scale entertainment productions, including Cirque du Soleil and serving as associate director and associate producer of Michael Jackson\'s "This Is It" concert, among others.
  • "He masterfully finds a point of intersection that allows us to grow and thrive in spite of the pain.

Medicenna Appoints Immuno-Oncology Expert Dr. Mann Muhsin as Chief Medical Officer

Retrieved on: 
Wednesday, May 12, 2021

It is a pleasure to welcome Mann to Medicenna and I am pleased to have him as part of the team.\xe2\x80\x9d\nDr.

Key Points: 
  • It is a pleasure to welcome Mann to Medicenna and I am pleased to have him as part of the team.\xe2\x80\x9d\nDr.
  • Muhsin commented, \xe2\x80\x9cI am excited to be\xc2\xa0joining Medicenna at this important time and am eager to begin leading the continued development of its growing clinical pipeline.
  • I look forward to working with my new colleagues to leverage the power of these platforms to deliver promising cytokine-based immunotherapies to patients with unmet medical needs.\xe2\x80\x9d\nDr.
  • Muhsin is an accomplished industry leader with more than 20 years of experience in medical practice and drug development and has an outstanding track record of innovation in oncology and immuno-oncology trial design.

DGAP-News: Evotec launches 'beLAB1407' to accelerate translational research from the UK's academic life science ecosystem in collaboration with Bristol Myers Squibb

Retrieved on: 
Thursday, May 6, 2021

"\nDr Rupert Vessey, Executive Vice President and President, Research and Early Development at Bristol Myers Squibb, commented: "This collaboration builds on our important connection to leading European universities.

Key Points: 
  • "\nDr Rupert Vessey, Executive Vice President and President, Research and Early Development at Bristol Myers Squibb, commented: "This collaboration builds on our important connection to leading European universities.
  • With beLAB1407, we are supporting U.K.-based universities that are exploring many interesting lines of scientific research and discovery.
  • That research combined with Evotec\'s proprietary data platforms has the potential to identify new and novel therapies for areas of unmet medical need.
  • "\nDr George Baxter, Chief Executive of Edinburgh Innovations, said: "This innovative collaboration represents the best of academic and industry collaboration.

LiveAction Acquires CounterFlow AI to Expand Network Security Offerings

Retrieved on: 
Tuesday, May 4, 2021

b'LiveAction , the leader in network performance management, today announced it has acquired CounterFlow AI , a leading network detection and response (NDR) provider.

Key Points: 
  • b'LiveAction , the leader in network performance management, today announced it has acquired CounterFlow AI , a leading network detection and response (NDR) provider.
  • \xe2\x80\x9cBusinesses today need end-to-end visibility for both network performance and security management, which is why CounterFlow AI\xe2\x80\x99s cutting-edge NDR capabilities are such a perfect match for our platform.
  • CounterFlow AI\xe2\x80\x99s unique security portfolio will help LiveAction partners and customers gain end-to-end network visibility into that traffic.
  • To learn more and see how LiveAction delivers unmatched network visibility, visit https://www.liveaction.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210504005296/en/\n'

Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results

Retrieved on: 
Monday, May 3, 2021

We are pleased to have completed our first U.S. commercial sales of IMCIVREE\xe2\x84\xa2 (setmelanotide) in the first quarter.\xe2\x80\x9d\nDr.

Key Points: 
  • We are pleased to have completed our first U.S. commercial sales of IMCIVREE\xe2\x84\xa2 (setmelanotide) in the first quarter.\xe2\x80\x9d\nDr.
  • We also remain on track to complete U.S. and EU regulatory submissions for BBS in the second half of 2021.
  • Rhythm did not generate any product revenues in the first quarter of 2020.\nR&D Expenses: R&D expenses were $19.9 million in the first quarter of 2021, as compared to $22.5 million in the first quarter of 2020.
  • Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity.

Nemysis Ltd Announces Appointment of Dr. Margit Holzer to Its Scientific Advisory Board

Retrieved on: 
Thursday, April 29, 2021

b'DUBLIN, April 29, 2021 /PRNewswire/ --Nemysis Ltdannounced today the appointment of Dr. Margit Holzer to its Scientific Advisory Board (SAB).\nDr.

Key Points: 
  • b'DUBLIN, April 29, 2021 /PRNewswire/ --Nemysis Ltdannounced today the appointment of Dr. Margit Holzer to its Scientific Advisory Board (SAB).\nDr.
  • "We look forward to her contribution as we approach the next phase of our company\'s growth.
  • "\n"I am honoured to join Nemysis as we strive to advance the quality of care available to patients with gluten intolerance," added Dr.
  • "\n"I am personally very pleased to welcome Dr. Holzer as an advisor to Nemysis," said Marco Cartolari, Chief Operating Officer of Nemysis.